Biogen Inc’s shock decision this week to bring its experimental Alzheimer’s drug back from the scrap heap was born out of “top secret” meetings, non-disclosure agreements and six months of hashing over trial data with scientists, regulators and statisticians, researchers told Reuters. Biogen had announced in March that it would terminate two large clinical trials of aducanumab because they were likely to fail. In the months that followed, Biogen kept its own trial investigators and committee overseeing the trial in the dark about the possibility that some patients had benefited from high doses of the therapy, researchers told …read more
Source:: Yahoo Finance
